Excalipoint Therapeutics: Seed+Develops next-generation T-cell engager therapies for cancer and autoimmune diseasesOct 4, 2026RoundOSExcalipoint TherapeuticsCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechChinaHealthtechAsiaSeed